ARTICLE | Company News
Alnylam, Hybridon deal
August 9, 2004 7:00 AM UTC
HBY granted ALNY an exclusive license to IP covering the use of RNAi to inhibit vascular endothelial growth factor (VEGF) for ophthalmic indications. HBY received an upfront payment and is eligible f...